Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows (in millions, except percentages):

	Year Ended December 31,
Net sales	2020		2019		2018
MedSurg	$	3,066	$	3,307	$	3,007
Rhythm and Neuro	2,752		3,140		3,041
Cardiovascular	3,876		4,208		3,777
Total net sales of reportable segments	9,694		10,654		9,823
All other (Specialty Pharmaceuticals)	219		81		n/a
Consolidated net sales	$	9,913	$	10,735	$	9,823

Reconciliation of depreciation by reportable segment to total [Table Text Block]

	Year Ended December 31,
Depreciation expense	2020		2019		2018
MedSurg	$	80	$	75	$	72
Rhythm and Neuro	96		92		91
Cardiovascular	154		138		133
Total depreciation expense of reportable segments	330		306		296
All other (Specialty Pharmaceuticals)	3		$	6	n/a
Consolidated depreciation expense	$	333	$	311	$	296

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

	Year Ended December 31,
Income (loss) before income taxes	2020		2019		2018
MedSurg	$	1,079	$	1,204	$	1,102
Rhythm and Neuro	439		666		655
Cardiovascular	661		1,137		1,117
Total operating income of reportable segments	2,179		3,007		2,875
All other (Specialty Pharmaceuticals)	143		56		n/a
Unallocated amounts:
Corporate expenses, including hedging activities	(405)		(264)		(372)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs	(1,208)		(582)		(398)
Amortization expense	(789)		(699)		(599)
Operating income (loss)	(80)		1,518		1,506
Other expense, net	1		(831)		(85)
Income (loss) before income taxes	$	(79)	$	687	$	1,422

Segment operating income as percentage of net sales [Table Text Block]

Operating income of reportable segments as a percentage of net sales of reportable segments	Year Ended December 31,
	2020		2019		2018
MedSurg	35.2	%	36.4	%	36.7	%
Rhythm and Neuro	15.9	%	21.2	%	21.5	%
Cardiovascular	17.1	%	27.0	%	29.6	%

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

	As of December 31,
Total assets	2020		2019
MedSurg	$	1,638	$	1,803
Rhythm and Neuro	1,827		1,873
Cardiovascular	2,461		2,535
Total assets of reportable segments	5,926		6,211
All other (Specialty Pharmaceuticals)	1,133		211
Goodwill	9,951		10,176
Other intangible assets, net	5,917		7,886
All other corporate assets	7,850		6,082
	$	30,777	$	30,565

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]

	As of December 31,
Long-lived assets	2020		2019		2018
U.S.	$	1,151	$	1,148	$	1,061
Ireland	382		327		242
Other countries	551		604		478
Property, plant and equipment, net	2,084		2,079		1,782
Goodwill	9,951		10,176		7,911
Other intangible assets, net	5,917		7,886		6,372
Operating lease right-of-use assets in Other long-term assets	458		336		—
	$	18,409	$	20,477	$	16,064